Cardiac Biomarkers Testing Global Market Report 2025

Description

Cardiac biomarkers testing involves assessing the levels of specific substances in the blood, aiding in the diagnosis, evaluation, and monitoring of individuals possibly experiencing acute coronary syndrome (ACS).

Key biomarkers in cardiac biomarkers testing include creatine kinase (CK-MB), troponins, myoglobin, natriuretic peptides (BNP and NT-proBNP), ischemia-modified albumin (IMA), and various others. Creatine kinase (CK-MB) is an enzyme analyzed through a blood test. These tests find applications in conditions such as congestive heart failure, acute coronary syndrome, myocardial infarction, atherosclerosis, among others, primarily utilized by hospitals and specialized clinics.

The cardiac biomarkers testing market research report is one of a series of new reports from The Business Research Company that provides cardiac biomarkers testing market statistics, including cardiac biomarkers testing industry global market size, regional shares, competitors with cardiac biomarkers testing market share, detailed cardiac biomarkers testing market segments, market trends, and opportunities, and any further data you may need to thrive in the cardiac biomarkers testing industry. This cardiac biomarkers testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The cardiac biomarkers testing market size has grown rapidly in recent years. It will grow from $13.48 billion in 2024 to $15.09 billion in 2025 at a compound annual growth rate (CAGR) of 12.0%. The growth in the historic period can be attributed to increasing incidence of cardiovascular diseases, aging population, awareness and education initiatives, government initiatives and healthcare policies, increasing healthcare expenditure.

The cardiac biomarkers testing market size is expected to see rapid growth in the next few years. It will grow to $23.75 billion in 2029 at a compound annual growth rate (CAGR) of 12.0%. The growth in the forecast period can be attributed to personalized medicine, rising global burden of cardiovascular diseases, integration of artificial intelligence (ai) in diagnostics, expansion of point-of-care testing, increasing emphasis on early disease detection. Major trends in the forecast period include technological advancements, advancements in ai-assisted diagnostics, point-of-care testing (POCT) growth, multiplexing capabilities, biomarker discovery and validation.

The anticipated rise in the prevalence of cardiovascular diseases is poised to drive the growth of the cardiac biomarkers testing market. Cardiovascular diseases, impacting the heart or blood vessels, necessitate quick and accurate diagnostic tools. Cardiac biomarker tests play a crucial role by assessing biomarker levels to promptly determine the severity and magnitude of a heart attack. As indicated by data from the American College of Cardiology in August 2022, the United States is expected to witness a considerable increase in the rates of cardiovascular risk factors and diseases by the year 2060. This projection underscores the anticipated surge in demand for cardiac biomarker testing solutions, aligning with the overall growth of the cardiac biomarkers testing market.

The growing demand for personalized medical solutions emerges as a significant driver propelling the cardiac biomarkers testing market forward. Personalized medicine, tailoring medical decisions and interventions to individual patients, is increasingly incorporating cardiac biomarkers testing for more precise cardiovascular care. This integration enhances prevention, early detection, and treatment strategies, addressing the specific needs of each patient. Notably, reports from October 2022 indicate a significant presence of over 75,000 genetic testing products and 300 personalized medicines, reflecting the expanding demand for personalized medicine solutions. This trend contributes to the sustained growth of the cardiac biomarkers testing market.

Major companies in the cardiac biomarker testing market are making strides in modern cardiovascular diagnostics to enhance the early detection, accuracy, and monitoring of heart-related conditions. These advancements aim to improve test sensitivity, decrease turnaround times, and provide more comprehensive insights into heart health, ultimately leading to better patient outcomes and more effective treatment plans. For example, in October 2023, Mindray Medical International Limited, a China-based medical device company, introduced high-sensitivity troponin I (hs-cTnI) and NT-proBNP to improve the diagnosis and management of cardiovascular diseases. High-sensitivity cardiac troponin I (hs-cTnI) is a protein that enters the bloodstream when the heart muscle sustains damage. NT-proBNP is a peptide produced by the heart in response to increased ventricular volume and pressure overload. The innovative features of hs-cTnI include its ability to detect low levels of cardiac troponin, which enhances the early diagnosis of myocardial infarction, while NT-proBNP offers critical insights into the severity of heart failure through its reaction to ventricular stress. These biomarkers significantly enhance clinical decision-making and patient outcomes in cardiovascular care.

Prominent companies in the cardiac biomarker testing market are strategically focusing on innovative products, with a particular emphasis on cardiac biomarkers, to drive revenue growth. Cardiac biomarkers, also referred to as cardiac enzymes, are substances released into the bloodstream in response to heart muscle damage, serving as crucial indicators in diagnosing and monitoring cardiovascular conditions. In October 2023, Shenzhen Mindray Bio-Medical Electronics Co., Ltd., a China-based company specializing in medical equipment and solutions, launched troponin I (hs-cTnI) and NT-proBNP cardiac biomarkers. The hs-cTn assay surpasses minimal requirements for sensitivity, accuracy, and reliability in identifying myocardial damage. These innovative products aim to enhance treatment for cardiovascular illnesses, providing reliable solutions that improve patient outcomes both within and beyond the realm of cardiovascular diseases.

In July 2024, Roche Holding AG, a pharmaceutical company based in Switzerland, acquired LumiraDx's Point of Care technology for an undisclosed amount. This acquisition aims to bolster Roche's diagnostic portfolio, especially in the realm of decentralized diagnostics. By incorporating LumiraDx's innovative point-of-care platform, Roche intends to enhance its capacity to deliver rapid and accurate testing at or near patient locations. LumiraDx Ltd., a healthcare company located in the UK, specializes in providing cardiac biomarker testing, including the NT-proBNP test.

Major companies operating in the cardiac biomarkers testing market include Abbott Laboratories, Bio-Rad Laboratories Inc., Danaher Corporation, F. Hoffmann-La Roche Ltd., Siemens Healthineers AG, Thermo Fisher Scientific Inc., Biomerieux SA, Becton Dickinson and Company, Randox Laboratories Ltd., Enzo Biochem Inc., Creative Diagnostics Inc., Merck Co. & KGaA, Beckman Coulter Inc., QIAGEN N.V., PerkinElmer Inc., Tosoh Corporation, Eurolyser Diagnostica GmbH, Cortez Diagnostics Inc., DIALAB GmbH, CardioGenics Holdings Inc., Lepu Medical Technology (Beijing) Co. Ltd., Biosynex SA, Charles River Laboratories, Quidel Corporation, Life Diagnostics, Trinity Biotech plc, Guangzhou Wondfo Biotech Co. Ltd., Nova Biomedical Corp., Ortho Clinical Diagnostics Inc., Sekisui Diagnostics Inc., Abcam plc, Bio-Techne Corporation

North America was the largest region in the cardiac biomarkers testing market in 2024. The regions covered in the cardiac biomarkers testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the cardiac biomarkers testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The cardiac biomarkers testing market includes revenues earned by entities by providing ischemia-modified albumin (IMA), peptides, and C-reactive protein (CRP) biomarkers testing. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Cardiac Biomarkers Testing Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on cardiac biomarkers testing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for cardiac biomarkers testing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The cardiac biomarkers testing market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Biomarkers Type: Creatine Kinase (CK-MB); Troponins; Myoglobin; Natriuretic Peptides (BNP And NT-proBNP); Ischemia Modified Albumin (IMA); Other Biomarkers Types
2) By Application: Congestive Heart Failure; Acute Coronary Syndrome; Myocardial Infarction; Atherosclerosis; Other Applications
3) By End-User: Hospitals; Specialty Clinics
Subsegments:
1) By Creatine Kinase (CK-MB): Total CK-MB; CK-MB Mass
2) By Troponins: Cardiac Troponin I (cTnI); Cardiac Troponin T (cTnT)
3) By Myoglobin: Total Myoglobin
4) By Natriuretic Peptides: B-Type Natriuretic Peptide (BNP); N-Terminal Pro B-Type Natriuretic Peptide (NT-ProBNP)
5) By Ischemia Modified Albumin (IMA): IMA Levels
6) By Other Biomarkers Types: C-Reactive Protein (CRP); Heart-Type Fatty Acid-Binding Protein (H-FABP); Soluble ST2
Companies Mentioned: Abbott Laboratories; Bio-Rad Laboratories Inc.; Danaher Corporation; F. Hoffmann-La Roche Ltd.; Siemens Healthineers AG
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r23232

1. Executive Summary

2. Cardiac Biomarkers Testing Market Characteristics

3. Cardiac Biomarkers Testing Market Trends And Strategies

4. Cardiac Biomarkers Testing Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Cardiac Biomarkers Testing Growth Analysis And Strategic Analysis Framework

5.1. Global Cardiac Biomarkers Testing PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Cardiac Biomarkers Testing Market Growth Rate Analysis
5.4. Global Cardiac Biomarkers Testing Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Cardiac Biomarkers Testing Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Cardiac Biomarkers Testing Total Addressable Market (TAM)

6. Cardiac Biomarkers Testing Market Segmentation

6.1. Global Cardiac Biomarkers Testing Market, Segmentation By Biomarkers Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Creatine Kinase (CK-MB)
Troponins
Myoglobin
Natriuretic Peptides (BNP and NT-proBNP)
Ischemia Modified albumin (IMA)
Other Biomarkers Types
6.2. Global Cardiac Biomarkers Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Congestive Heart Failure
Acute Coronary Syndrome
Myocardial Infarction
Atherosclerosis
Other Applications
6.3. Global Cardiac Biomarkers Testing Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Specialty Clinics
6.4. Global Cardiac Biomarkers Testing Market, Sub-Segmentation Of Creatine Kinase (CK-MB), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Total CK-MB
CK-MB Mass
6.5. Global Cardiac Biomarkers Testing Market, Sub-Segmentation Of Troponins, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Cardiac Troponin I (cTnI)
Cardiac Troponin T (cTnT)
6.6. Global Cardiac Biomarkers Testing Market, Sub-Segmentation Of Myoglobin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Total Myoglobin
6.7. Global Cardiac Biomarkers Testing Market, Sub-Segmentation Of Natriuretic Peptides, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
B-Type Natriuretic Peptide (BNP)
N-Terminal Pro B-Type Natriuretic Peptide (NT-ProBNP)
6.8. Global Cardiac Biomarkers Testing Market, Sub-Segmentation Of Ischemia Modified Albumin (IMA), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
IMA Levels
6.9. Global Cardiac Biomarkers Testing Market, Sub-Segmentation Of Other Biomarkers Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
C-Reactive Protein (CRP)
Heart-Type Fatty Acid-Binding Protein (H-FABP)
Soluble ST2

7. Cardiac Biomarkers Testing Market Regional And Country Analysis

7.1. Global Cardiac Biomarkers Testing Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Cardiac Biomarkers Testing Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Cardiac Biomarkers Testing Market

8.1. Asia-Pacific Cardiac Biomarkers Testing Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Cardiac Biomarkers Testing Market, Segmentation By Biomarkers Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Cardiac Biomarkers Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Cardiac Biomarkers Testing Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Cardiac Biomarkers Testing Market

9.1. China Cardiac Biomarkers Testing Market Overview
9.2. China Cardiac Biomarkers Testing Market, Segmentation By Biomarkers Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Cardiac Biomarkers Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Cardiac Biomarkers Testing Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Cardiac Biomarkers Testing Market

10.1. India Cardiac Biomarkers Testing Market, Segmentation By Biomarkers Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Cardiac Biomarkers Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Cardiac Biomarkers Testing Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Cardiac Biomarkers Testing Market

11.1. Japan Cardiac Biomarkers Testing Market Overview
11.2. Japan Cardiac Biomarkers Testing Market, Segmentation By Biomarkers Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Cardiac Biomarkers Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Cardiac Biomarkers Testing Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Cardiac Biomarkers Testing Market

12.1. Australia Cardiac Biomarkers Testing Market, Segmentation By Biomarkers Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Cardiac Biomarkers Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Cardiac Biomarkers Testing Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Cardiac Biomarkers Testing Market

13.1. Indonesia Cardiac Biomarkers Testing Market, Segmentation By Biomarkers Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Cardiac Biomarkers Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Cardiac Biomarkers Testing Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Cardiac Biomarkers Testing Market

14.1. South Korea Cardiac Biomarkers Testing Market Overview
14.2. South Korea Cardiac Biomarkers Testing Market, Segmentation By Biomarkers Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Cardiac Biomarkers Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Cardiac Biomarkers Testing Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Cardiac Biomarkers Testing Market

15.1. Western Europe Cardiac Biomarkers Testing Market Overview
15.2. Western Europe Cardiac Biomarkers Testing Market, Segmentation By Biomarkers Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Cardiac Biomarkers Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Cardiac Biomarkers Testing Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Cardiac Biomarkers Testing Market

16.1. UK Cardiac Biomarkers Testing Market, Segmentation By Biomarkers Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Cardiac Biomarkers Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Cardiac Biomarkers Testing Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Cardiac Biomarkers Testing Market

17.1. Germany Cardiac Biomarkers Testing Market, Segmentation By Biomarkers Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Cardiac Biomarkers Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Cardiac Biomarkers Testing Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Cardiac Biomarkers Testing Market

18.1. France Cardiac Biomarkers Testing Market, Segmentation By Biomarkers Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Cardiac Biomarkers Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Cardiac Biomarkers Testing Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Cardiac Biomarkers Testing Market

19.1. Italy Cardiac Biomarkers Testing Market, Segmentation By Biomarkers Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Cardiac Biomarkers Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Cardiac Biomarkers Testing Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Cardiac Biomarkers Testing Market

20.1. Spain Cardiac Biomarkers Testing Market, Segmentation By Biomarkers Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Cardiac Biomarkers Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Cardiac Biomarkers Testing Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Cardiac Biomarkers Testing Market

21.1. Eastern Europe Cardiac Biomarkers Testing Market Overview
21.2. Eastern Europe Cardiac Biomarkers Testing Market, Segmentation By Biomarkers Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Cardiac Biomarkers Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Cardiac Biomarkers Testing Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Cardiac Biomarkers Testing Market

22.1. Russia Cardiac Biomarkers Testing Market, Segmentation By Biomarkers Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Cardiac Biomarkers Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Cardiac Biomarkers Testing Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Cardiac Biomarkers Testing Market

23.1. North America Cardiac Biomarkers Testing Market Overview
23.2. North America Cardiac Biomarkers Testing Market, Segmentation By Biomarkers Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Cardiac Biomarkers Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Cardiac Biomarkers Testing Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Cardiac Biomarkers Testing Market

24.1. USA Cardiac Biomarkers Testing Market Overview
24.2. USA Cardiac Biomarkers Testing Market, Segmentation By Biomarkers Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Cardiac Biomarkers Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Cardiac Biomarkers Testing Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Cardiac Biomarkers Testing Market

25.1. Canada Cardiac Biomarkers Testing Market Overview
25.2. Canada Cardiac Biomarkers Testing Market, Segmentation By Biomarkers Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Cardiac Biomarkers Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Cardiac Biomarkers Testing Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Cardiac Biomarkers Testing Market

26.1. South America Cardiac Biomarkers Testing Market Overview
26.2. South America Cardiac Biomarkers Testing Market, Segmentation By Biomarkers Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Cardiac Biomarkers Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Cardiac Biomarkers Testing Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Cardiac Biomarkers Testing Market

27.1. Brazil Cardiac Biomarkers Testing Market, Segmentation By Biomarkers Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Cardiac Biomarkers Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Cardiac Biomarkers Testing Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Cardiac Biomarkers Testing Market

28.1. Middle East Cardiac Biomarkers Testing Market Overview
28.2. Middle East Cardiac Biomarkers Testing Market, Segmentation By Biomarkers Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Cardiac Biomarkers Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Cardiac Biomarkers Testing Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Cardiac Biomarkers Testing Market

29.1. Africa Cardiac Biomarkers Testing Market Overview
29.2. Africa Cardiac Biomarkers Testing Market, Segmentation By Biomarkers Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Cardiac Biomarkers Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Cardiac Biomarkers Testing Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Cardiac Biomarkers Testing Market Competitive Landscape And Company Profiles

30.1. Cardiac Biomarkers Testing Market Competitive Landscape
30.2. Cardiac Biomarkers Testing Market Company Profiles
- 30.2.1. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Bio-Rad Laboratories Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Danaher Corporation Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Siemens Healthineers AG Overview, Products and Services, Strategy and Financial Analysis

31. Cardiac Biomarkers Testing Market Other Major And Innovative Companies

31.1. Thermo Fisher Scientific Inc.
31.2. Biomerieux SA
31.3. Becton Dickinson and Company
31.4. Randox Laboratories Ltd.
31.5. Enzo Biochem Inc.
31.6. Creative Diagnostics Inc.
31.7. Merck Co. & KGaA
31.8. Beckman Coulter Inc.
31.9. QIAGEN N.V.
31.10. PerkinElmer Inc.
31.11. Tosoh Corporation
31.12. Eurolyser Diagnostica GmbH
31.13. Cortez Diagnostics Inc.
31.14. DIALAB GmbH
31.15. CardioGenics Holdings Inc.

32. Global Cardiac Biomarkers Testing Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Cardiac Biomarkers Testing Market

34. Recent Developments In The Cardiac Biomarkers Testing Market

35. Cardiac Biomarkers Testing Market High Potential Countries, Segments and Strategies

35.1 Cardiac Biomarkers Testing Market In 2029 - Countries Offering Most New Opportunities
35.2 Cardiac Biomarkers Testing Market In 2029 - Segments Offering Most New Opportunities
35.3 Cardiac Biomarkers Testing Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer